STRO-002-GM1: Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers (clinicaltrials.gov) - Aug 1, 2024 - P1 | N=136 | Completed | Sponsor: Sutro Biopharma, Inc. | Active, not recruiting ➔ Completed | Trial completion date: Nov 2024 ➔ Jun 2024
Metastases • Trial completion • Trial completion date • Endometrial Cancer • Fallopian Tube Cancer • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor
|